flutamide has been researched along with Local Neoplasm Recurrence in 40 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The vast majority of residual tumors were poorly differentiated (Gleason score ≥ 8)." | 2.76 | Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial. ( Ahlgren, G; Angelsen, A; Bergh, A; Haugen, OA; Solberg, A; Tasdemir, I; Viset, T; Widmark, A, 2011) |
| "Men with BR of prostate cancer after radical prostatectomy (RP) or radiation (RT) were treated with androgen deprivation therapy (ADT) comprised of leuprolide and flutamide." | 2.75 | Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. ( Etzioni, RD; Gulati, R; Higano, CS; Jiang, P; Nelson, PS; Russell, KJ; Tam, S; Telesca, D; Yu, EY, 2010) |
| "Men with localized but unfavorable-risk prostate cancer who were treated with RT and 6 months of planned combined AST appear to have an increased risk of recurrence when treated with less than as compared with 6 months of the antiandrogen." | 2.73 | Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. ( Chen, MH; D'Amico, AV; Kantoff, PW; Loffredo, B; Renshaw, AA, 2008) |
| "Patients with hormone relapsed prostate cancer (HRPC) are often treated with flutamide or diethylstilboestrol." | 2.70 | Prospective randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancer. ( Basketter, V; Burns-Cox, N; Higgins, B; Holmes, S, 2002) |
| "Patient data related to prostatic intraepithelial neoplasia were analyzed." | 2.69 | Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance. ( Balaji, KC; Bastar, A; Fair, WR; Rabbani, F; Tsai, H, 1999) |
| "Regarding local disease progression, the advantage for the use of NHT approached but did not reach statistical significance:18 of 189 patients (10%) in the NHT group and 33 of 209 patients (16%) in the RP group (P = 0." | 2.69 | Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience. ( Debruyne, FM; Witjes, WP, 2000) |
| "To assess the pathological staging and biochemical progression-free survival (assessed using serum prostate-specific antigen level) of patients with clinically localized prostate cancer using neoadjuvant androgen deprivation therapy (ADT) in combination with radical retropubic prostatectomy (RRP)." | 2.68 | Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. ( Begg, CB; Cookson, MS; Dalbagni, G; Fair, WR; Herr, H; Reuter, VE; Russo, P; Sheinfeld, J; Sogani, PC, 1997) |
| "Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer death in men, following lung cancer." | 2.42 | Clinical strategies in the management of biochemical recurrence after radical prostatectomy. ( Culkin, DJ; Zimmerman, RA, 2003) |
| "124 patients with prostate cancer were diagnosed and followed at Kobe City General Hospital between 1995 and 1997." | 1.31 | Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma. ( Fujikawa, K; Fukuzawa, S; Matsui, Y; Takeuchi, H, 2000) |
| "To compare disease progression and survival of patients with stage D1 adenocarcinoma after treatment with either early androgen ablation alone or combined with radical prostatectomy." | 1.30 | Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer. ( Lubos, W; Schmeller, N, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.00) | 18.7374 |
| 1990's | 10 (25.00) | 18.2507 |
| 2000's | 18 (45.00) | 29.6817 |
| 2010's | 10 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Verhoven, B | 1 |
| Yan, Y | 1 |
| Ritter, M | 1 |
| Khor, LY | 1 |
| Hammond, E | 1 |
| Jones, C | 1 |
| Amin, M | 1 |
| Bahary, JP | 2 |
| Zeitzer, K | 1 |
| Pollack, A | 1 |
| Hirano, D | 1 |
| Hasegawa, R | 1 |
| Satoh, K | 1 |
| Mochida, J | 1 |
| Yamanaka, Y | 1 |
| Hirakata, H | 1 |
| Yamaguchi, K | 1 |
| Sugimoto, S | 1 |
| Kawata, N | 1 |
| Takahashi, S | 1 |
| Matsumoto, K | 1 |
| Hagiwara, M | 1 |
| Hayakawa, N | 1 |
| Tanaka, N | 1 |
| Ito, Y | 1 |
| Maeda, T | 1 |
| Ninomiya, A | 1 |
| Nagata, H | 1 |
| Nakamura, S | 1 |
| Locke, JA | 1 |
| Dal Pra, A | 1 |
| Supiot, S | 1 |
| Warde, P | 1 |
| Bristow, RG | 1 |
| Krauss, DJ | 1 |
| Hu, C | 1 |
| Souhami, L | 1 |
| Gore, EM | 1 |
| Chafe, SM | 1 |
| Leibenhaut, MH | 1 |
| Narayan, S | 1 |
| Torres-Roca, J | 1 |
| Michalski, J | 1 |
| Zeitzer, KL | 1 |
| Donavanik, V | 1 |
| Sandler, H | 1 |
| McGowan, DG | 1 |
| Jones, CU | 1 |
| Shipley, WU | 1 |
| D'Amico, AV | 3 |
| Chen, MH | 2 |
| Renshaw, AA | 2 |
| Loffredo, B | 1 |
| Kantoff, PW | 3 |
| Suzuki, H | 2 |
| Okihara, K | 1 |
| Miyake, H | 1 |
| Fujisawa, M | 1 |
| Miyoshi, S | 1 |
| Matsumoto, T | 1 |
| Fujii, M | 1 |
| Takihana, Y | 1 |
| Usui, T | 1 |
| Matsuda, T | 1 |
| Ozono, S | 1 |
| Kumon, H | 1 |
| Ichikawa, T | 2 |
| Miki, T | 1 |
| Bañez, LL | 1 |
| Blake, GW | 1 |
| McLeod, DG | 1 |
| Crawford, ED | 2 |
| Moul, JW | 2 |
| Loffredo, M | 2 |
| Gannon, PO | 1 |
| Poisson, AO | 1 |
| Delvoye, N | 1 |
| Lapointe, R | 1 |
| Mes-Masson, AM | 1 |
| Saad, F | 1 |
| Yee, DS | 1 |
| Lowrance, WT | 1 |
| Eastham, JA | 1 |
| Maschino, AC | 1 |
| Cronin, AM | 1 |
| Rabbani, F | 2 |
| Yu, EY | 1 |
| Gulati, R | 1 |
| Telesca, D | 1 |
| Jiang, P | 1 |
| Tam, S | 1 |
| Russell, KJ | 1 |
| Nelson, PS | 1 |
| Etzioni, RD | 1 |
| Higano, CS | 1 |
| Solberg, A | 1 |
| Haugen, OA | 1 |
| Viset, T | 1 |
| Bergh, A | 1 |
| Tasdemir, I | 1 |
| Ahlgren, G | 1 |
| Widmark, A | 1 |
| Angelsen, A | 1 |
| Okegawa, T | 1 |
| Nutahara, K | 1 |
| Higashihara, E | 1 |
| Jang, JW | 1 |
| Hwang, WT | 1 |
| Guzzo, TJ | 1 |
| Wein, AJ | 2 |
| Haas, NB | 1 |
| Both, S | 1 |
| Vapiwala, N | 1 |
| Burns-Cox, N | 1 |
| Basketter, V | 1 |
| Higgins, B | 1 |
| Holmes, S | 1 |
| Meineke, V | 1 |
| Köhn, FM | 1 |
| Pickl, U | 1 |
| Ring, J | 1 |
| Vogt, HJ | 1 |
| Barqawi, AB | 1 |
| Ziada, A | 1 |
| Handel, L | 1 |
| Kojima, S | 1 |
| Akakura, K | 1 |
| Shimbo, M | 1 |
| Ito, H | 1 |
| Zimmerman, RA | 1 |
| Culkin, DJ | 1 |
| Enepekides, DJ | 1 |
| Spry, NA | 1 |
| Kristjanson, L | 1 |
| Hooton, B | 1 |
| Hayden, L | 1 |
| Neerhut, G | 1 |
| Gurney, H | 1 |
| Corica, T | 1 |
| Korbel, E | 1 |
| Weinstein, S | 1 |
| McCaul, K | 1 |
| Ryan, CJ | 1 |
| Smith, A | 1 |
| Lal, P | 1 |
| Satagopan, J | 1 |
| Reuter, V | 1 |
| Scardino, P | 1 |
| Gerald, W | 1 |
| Scher, HI | 2 |
| Halabi, S | 1 |
| Vollmer, R | 1 |
| McMahon, E | 1 |
| Sanford, B | 1 |
| Archer, L | 1 |
| Vogelzang, NJ | 1 |
| Small, EJ | 1 |
| Cher, ML | 1 |
| Shinohara, K | 1 |
| Breslin, S | 1 |
| Vapnek, J | 1 |
| Carroll, PR | 1 |
| Whittington, R | 1 |
| Malkowicz, B | 1 |
| Barnes, MM | 1 |
| Broderick, GA | 1 |
| Van Arsdalen, K | 1 |
| Dougherty, MJ | 1 |
| Zhang, ZF | 1 |
| Nanus, D | 1 |
| Kelly, WK | 1 |
| Schmeller, N | 1 |
| Lubos, W | 1 |
| Cookson, MS | 1 |
| Sogani, PC | 1 |
| Russo, P | 1 |
| Sheinfeld, J | 1 |
| Herr, H | 1 |
| Dalbagni, G | 1 |
| Reuter, VE | 1 |
| Begg, CB | 1 |
| Fair, WR | 2 |
| Corn, BW | 1 |
| Valicenti, RK | 1 |
| Mulholland, SG | 1 |
| Hyslop, T | 1 |
| Gomella, L | 1 |
| Eulau, SM | 1 |
| Tate, DJ | 1 |
| Stamey, TA | 1 |
| Bagshaw, MA | 1 |
| Hancock, SL | 1 |
| Balaji, KC | 1 |
| Tsai, H | 1 |
| Bastar, A | 1 |
| Bhayani, SB | 1 |
| Andriole, GL | 1 |
| Fujikawa, K | 1 |
| Matsui, Y | 1 |
| Fukuzawa, S | 1 |
| Takeuchi, H | 1 |
| Debruyne, FM | 1 |
| Witjes, WP | 1 |
| Pilepich, MV | 1 |
| Winter, K | 1 |
| John, MJ | 1 |
| Mesic, JB | 1 |
| Sause, W | 1 |
| Rubin, P | 1 |
| Lawton, C | 1 |
| Machtay, M | 1 |
| Grignon, D | 1 |
| Soloway, MS | 1 |
| Pareek, K | 1 |
| Sharifi, R | 1 |
| Wajsman, Z | 1 |
| McLeod, D | 1 |
| Wood, DP | 1 |
| Puras-Baez, A | 1 |
| Prout, GR | 1 |
| Kliman, B | 1 |
| Daly, JJ | 1 |
| Maclaughlin, RA | 1 |
| Griffin, PP | 1 |
| Haefliger, JM | 1 |
| Labrie, F | 1 |
| Dupont, A | 1 |
| Bélanger, A | 1 |
| Cusan, L | 1 |
| Brochu, M | 1 |
| Turina, E | 1 |
| Pinault, S | 1 |
| Lacourciere, Y | 1 |
| Emond, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Trial of External Beam of Radiotherapy +/- Total Androgen Suppression for High Risk Clinically Organ-Confined Prostate Cancer[NCT00116220] | Phase 3 | 206 participants (Actual) | Interventional | 1995-09-30 | Completed | ||
| Prospective Study of Natural Killer Cells in Patients With Metastatic Prostate Cancer: Relationship With Survival and Response Time to Castration[NCT02963155] | 30 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
| PROGNOSTIC SIGNIFICANCE OF ENDORECTAL MRI IN PREDICTING OUTCOME AFTER COMBINED RADIATION AND ANDROGEN SUPPRESSION FOR PROSTATE CANCER: A PROSPECTIVE PHASE II STUDY[NCT00002889] | Phase 2 | 180 participants (Actual) | Interventional | 1997-05-31 | Completed | ||
| Phase II Randomized Clinical Trial Comparing 3-D Conformal Radiation Therapy (RT) vs. Intensity Modulated Radiation Therapy in Post- Prostatectomy Prostate Cancer Patients[NCT02678520] | Phase 2 | 0 participants (Actual) | Interventional | 2015-12-31 | Withdrawn (stopped due to PI no longer at institution. Study terminated prior to enrolling subjects.) | ||
| Phase III Multicenter Randomized Trial of Adjuvant Androgen Deprivation in Combination With Three-dimensional Conformal Radiotherapy Doses in High and Intermediate Risk Localized Prostate Cancer.[NCT02175212] | Phase 3 | 362 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy Followed by HDR Brachy Boost for High Risk Adenocarcinoma of the Prostate (PCS-VI)[NCT02303327] | Phase 3 | 296 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| A Phase II Study of Proton-Based Radiation Therapy With Elective Pelvic Nodal Irradiation, Concomitant Docetaxel, and Adjuvant Androgen Deprivation for High-Risk Prostate Adenocarcinoma[NCT01040624] | 77 participants (Actual) | Interventional | 2009-12-31 | Completed | |||
| Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy[NCT00969111] | 70 participants (Anticipated) | Interventional | 2009-08-31 | Recruiting | |||
| An Expanded Phase II Study of Hypofractionated Dose Intense Image Guided Proton Radiation Therapy for Low and Intermediate Risk Adenocarcinoma of the Prostate[NCT01368055] | 361 participants (Actual) | Interventional | 2011-09-30 | Active, not recruiting | |||
| A Phase II Study of Hypofractionated Image Guided Proton Radiation Therapy for Low and Intermediate Risk Adenocarcinoma of the Prostate[NCT00693238] | 228 participants (Actual) | Interventional | 2008-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Biochemical relapse was defined as the time from inclusion in the study (randomization) until the patient meets criteria for Biochemical failure (Phoenix criteria: PSA nadir plus 2 ng/ml). (NCT02175212)
Timeframe: 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Long Term Androgen Deprivation | 90 |
| Short Term Androgen Deprivation | 81 |
Cause-specific survival included all deaths from prostate cancer or treatment complications, and deaths from unknown causes in patients with either active cancer or a previously documented relapse (NCT02175212)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Long Term Androgen Deprivation | 177 |
| Short Term Androgen Deprivation | 173 |
Metastasis free survival: defined as the time from inclusion in the study (randomization) until the appearance of distant metastases: a positive result in any of the tests performed (scintigraphy, chest radiography, thorax, abdominal and pelvic CT and MRI). (NCT02175212)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Long Term Androgen Deprivation | 94 |
| Short Term Androgen Deprivation | 83 |
Overall Survival: defined as the time that elapses from the patient enters the study until the patient dies from any cause. (NCT02175212)
Timeframe: 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Long Term Androgen Deprivation | 95 |
| Short Term Androgen Deprivation | 86 |
"Defined as the maximal rectal, urinary and cardiovascular (CV) toxicity per patient more than 90 days after completion of RT.~Scoring scales used were the radiation morbidity scoring criteria of the European Organization for Research and Treatment of Cancer-Radiation Therapy Oncology Group (EORTC/RTOG) and the Common Terminology Criteria for Adverse Events (CTCAEs) v 3.0 for the remained toxicity.~CV events were defined according to the World Health Organization criteria" (NCT02175212)
Timeframe: 5 years
| Intervention | percentage of patients (Number) | ||
|---|---|---|---|
| Grade 2 of more rectal toxicity | Grade 2 of more urinary toxicity | Cardiovascular | |
| Long Term Androgen Deprivation | 11.1 | 8.2 | 17.6 |
| Short Term Androgen Deprivation | 7.6 | 7.3 | 7.2 |
Number of participants that experienced acute grade 3 or higher, treatment-related toxicity based on CTCAE version 3.0 criteria. (NCT01040624)
Timeframe: 6 months after the completion of radiation therapy
| Intervention | participants (Number) |
|---|---|
| HR-A | 1 |
| HR-B | 3 |
(NCT00693238)
Timeframe: 6 months after the end of radiation therapy
| Intervention | Participants (Number) |
|---|---|
| Low Risk Proton Radiation | 0 |
| Intermediate Risk Proton Radiation | 0 |
5 reviews available for flutamide and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy: report of 52 cases and literature review.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineopla | 2014 |
Synergistic action of image-guided radiotherapy and androgen deprivation therapy.
Topics: Androgen Antagonists; Androstenes; Benzamides; Biomarkers; Combined Modality Therapy; Dose-Response | 2015 |
Clinical strategies in the management of biochemical recurrence after radical prostatectomy.
Topics: Androgen Antagonists; Antifungal Agents; Cytochrome P-450 Enzyme System; Disease-Free Survival; Flut | 2003 |
Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer.
Topics: Aminoglutethimide; Androgen Antagonists; Clinical Trials as Topic; Flutamide; Humans; Male; Neoplasm | 1996 |
Hormonal manipulation for rising PSA after radical prostatectomy.
Topics: Androgen Antagonists; Anilides; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Flutamide | 1999 |
19 trials available for flutamide and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cell Proliferatio | 2013 |
Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Biopsy; Combined Modality Therapy; Di | 2015 |
Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy | 2008 |
Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Pr | 2009 |
Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause o | 2009 |
Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Epidemiologic Methods; Flutamide; Goserelin; H | 2010 |
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal | 2010 |
Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Combined Modality The | 2011 |
Prospective randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Diethylstilbestrol; Flutamide; Humans; | 2002 |
Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hor | 2003 |
p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Mi | 2008 |
High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Disease-Free Survival; Flutamide; Follow-Up Studies | 1995 |
Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; | 1997 |
Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
Topics: Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Androgen Antagonists; Antineoplastic Age | 1998 |
Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance.
Topics: Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up Studies; Humans; Leupr | 1999 |
Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
Topics: Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease | 2000 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up | 2002 |
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up | 2002 |
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up | 2002 |
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up | 2002 |
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up | 2002 |
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up | 2002 |
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up | 2002 |
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up | 2002 |
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up | 2002 |
[Randomized study comparing zoladex versus zoladex plus flutamide in treatment of advanced cancer of the prostate].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Flutamide; Gosere | 1992 |
16 other studies available for flutamide and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chromogranin A; Flutamide; Humans; Male; M | 2014 |
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flu | 2008 |
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.
Topics: Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Cyproterone; Flutamide; Humans; Ki | 2009 |
Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Chlormadin | 2010 |
Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
Topics: Analysis of Variance; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-Free Surviv | 2012 |
[Malignant priapism as a sign of a recurrent prostate cancer. Differential diagnosis of induratio penis plastica].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Dia | 2003 |
Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; | 2004 |
Recent advances in the treatment of juvenile angiofibroma.
Topics: Angiofibroma; Antineoplastic Agents, Hormonal; Endoscopy; Flutamide; Humans; Nasopharyngeal Neoplasm | 2004 |
Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer.
Topics: Aged; Androgen Antagonists; Flutamide; Humans; Leuprolide; Longitudinal Studies; Male; Middle Aged; | 2006 |
Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Flutamide; Gene Expression | 2006 |
Combined hormonal and radiation therapy for lymph node-positive prostate cancer.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Diethylstilbestrol; Disease-Free Survival; Flutamid | 1995 |
Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease Progressio | 1997 |
Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality | 1998 |
Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma.
Topics: Aged; Antineoplastic Agents, Hormonal; Flutamide; Humans; Male; Middle Aged; Neoplasm Recurrence, Lo | 2000 |
In vitro uptake of 3H testosterone and its conversion to dihydrotestosterone by prostatic carcinoma and other tissues.
Topics: Aged; Culture Techniques; Diethylstilbestrol; Dihydrotestosterone; Flutamide; Humans; Lymphatic Meta | 1976 |
Anti-hormone treatment for prostate cancer relapsing after treatment with flutamide and castration. Addition of aminoglutethimide and low dose hydrocortisone to combination therapy.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Flutam | 1989 |